Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection.

Scandinavian journal of gastroenterology - 1 Dec 2014

Farnik Harald, Ferreirós Nerea, Labocha Sandra, Geisslinger Gerd, Zeuzem Stefan, Sarrazin Christoph, Vermehren Johannes

Abstract excerpt

OBJECTIVE: Telaprevir (TVR)-based triple therapy has substantially improved cure rates of hepatitis C virus (HCV) genotype 1 infection but side effects are frequent and often severe. Therefore, response predictors are needed for early identification of patients not responding to TVR-based triple therapy. MATERIAL AND METHODS: Forty-five patients (mean age: 54 ± 13 years; male gender: 60%; treatment-experienced:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Logistic Models

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Viral Load

Source

Identifiers

PMID: 25384840
DOI: 10.3109/00365521.2014.978363

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection.PMID 25384840Read ↗

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.Semantic proximity Read ↗

Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.Semantic proximity Read ↗

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Semantic proximity Read ↗

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.Semantic proximity Read ↗

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.Semantic proximity Read ↗

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.Semantic proximity Read ↗

Telaprevir for previously treated chronic HCV infection.Semantic proximity Read ↗

Telaprevir for retreatment of HCV infection.Semantic proximity Read ↗

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.Semantic proximity Read ↗

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.Semantic proximity Read ↗

Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.Semantic proximity Read ↗

The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.